Key result
Multiplexed 3ABC antibody assay matches commercial ELISA performance for foot-and-mouth disease surveillance.
Cross-Sectional (n=198)
A multiplexed nonstructural protein serological assay demonstrates comparable performance to a commercial ELISA for differentiating foot-and-mouth disease virus-infected and vaccinated animals.
No takes yet. Share an insight, caveat, or question.
Supports multiplex assay development for FMD DIVA testing in animals; leaves open prospective field validation before surveillance adoption.
Perkins et al. (2007) conducted a cross-sectional in Foot-and-mouth disease (n=198). Multiplexed nonstructural protein antibody assay vs. Commercially available nonstructural protein 3ABC ELISA (Cedi test) was evaluated on Diagnostic specificity and sensitivity. The multiplexed nonstructural protein antibody assay's 3ABC signature showed performance comparable to a commercially available 3ABC ELISA for foot-and-mouth disease serological surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: